chufangao/CTO huggingface dataset:
Clinical trial NCT04662060: COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol
Official title: COVID-19 Outpatient Pragmatic Platform Study (COPPS): A Pragmatic Multi-arm, Adaptive, Phase 2, Blinded, Randomized Placebo-controlled Platform Trial to Assess the Efficacy of Different Investigational Therapeutics in Reducing Time to Disease Resolution or Viral Load Cessation, as Compared to Standard Supportive Care in Outpatients With COVID-19
Acronym: COPPS
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 120.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-23
Primary completion date: 2022-05-03
Completion date: 2023-02-02
Baseline population: Intent-to-treat population (all randomized participants)
Plan to share individual participant data: NO
Clinical trial NCT03340974: Pilot Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer
Official title: An Adaptive Phase I/II Dose Escalation Trial of Stereotactic Body Radiation Therapy in Combination With Radiomodulating Agent GC4419 in Locally Advanced Pancreatic Adenocarcinoma
Sponsor: Galera Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 42.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-02-12
Primary completion date: 2020-08-21
Completion date: 2021-05-26
Plan to share individual participant data: NO
Clinical trial NCT03943290: Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX)
Official title: An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) Previously Enrolled in Study A083-02 and in Patients With Charcot-Marie Tooth (CMT) Disease Types 1 and X Previously Enrolled in Study A083-03
Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Investigation of ACE-083 for use in patients with CMT and FSHD is being discontinued in this extension study as functional secondary endpoints were not achieved in the A083-023 or A083-03 trial (the parent trials).
Enrollment: 62.0 (ACTUAL)
Number of arms: 9.0
Start date: 2019-05-10
Primary completion date: 2020-03-11
Completion date: 2020-03-11
Baseline population: The safety population was used for baseline analysis- The Safety Population consisted of all participants enrolled/randomized in the study who received at least 1 dose of study drug.
Limitations and caveats: In this open-label, multicenter, phase 2 extension study in participants with FSHD and CMT (types 1 and X), treatment with ACE-083 q4w or q8w was generally safe and well tolerated. Participants were discontinued from this study when their respective parent studies were terminated by the sponsor, and as such, this study was also terminated. Due to premature termination of this study, insufficient efficacy data were obtained to enable meaningful efficacy analyses.
Clinical trial NCT04362189: Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19
Official title: A Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19
Sponsor: Hope Biosciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: No need to continue with the availability of the COVID-19 VACCINE
Enrollment: 48.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-06-30
Primary completion date: 2021-09-30
Completion date: 2021-09-30
Baseline population: Summary of baseline characteristics for all enrolled subjects.
Plan to share individual participant data: NO
Clinical trial NCT02389465: Stress and Inflammation in Late-Life Depression
Official title: Stress and Inflammation in the Pathophysiology of Late Life Depression
Acronym: S&I
Sponsor: University of Pennsylvania (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 119.0 (ACTUAL)
Number of arms: 2.0
Start date: 2014-08-31
Primary completion date: 2022-07-18
Completion date: 2022-07-18
Clinical trial NCT03825380: Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients
Official title: Efficacy and Safety Assessment of T4032 Versus Lumigan® in Ocular Hypertensive or Glaucomatous Patients
Sponsor: Laboratoires Thea (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 485.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-23
Primary completion date: 2021-02-03
Completion date: 2021-02-24
Clinical trial NCT03240861: Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer
Official title: Adoptive Transfer of NY-ESO-1 TCR Engineered Peripheral Blood Mononuclear Cells (PBMC) and Peripheral Blood Stem Cells (PBSC) After a Myeloablative Conditioning Regimen, With Administration of Interleukin-2, in Patients With Advanced Malignancies
Acronym: NYESO SCT
Sponsor: Jonsson Comprehensive Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: slow accrual
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-07-26
Primary completion date: 2023-10-19
Completion date: 2023-10-19
Clinical trial NCT04620473: Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Official title: Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal cancer-a Prospective, Open, Single Center and Randomized Controlled Phase Ⅱ Clinical Trial
Sponsor: Shanghai Minimally Invasive Surgery Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: No approval from ethical committee
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-11-01
Primary completion date: 2023-12-01
Completion date: 2024-10-01
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04039113: Tezepelumab COPD Exacerbation Study
Official title: A Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) (COURSE)
Acronym: COURSE
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 337.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-07-30
Primary completion date: 2023-11-10
Completion date: 2024-01-31
Clinical trial NCT05393089: Study of AGN-190584 Eye Drops to Assess Safety and Efficacy in Participants Aged 40-80 Years With Pseudophakic Presbyopia
Official title: A Phase 2, Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of AGN-190584 in Subjects With Pseudophakic Presbyopia
Acronym: ARIES
Sponsor: Allergan (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Business Decision
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-09
Primary completion date: 2023-04-04
Completion date: 2023-04-04
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Clinical trial NCT00437359: Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer
Official title: Antiestrogen vs Aromatase Inhibitor After Chemotherapy for Adjuvant Setting: Efficacy of Endocrine Therapy After Chemotherapy in Postoperative Adjuvant Therapy for Breast Cancer
Sponsor: Japan Breast Cancer Research Network (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Enrollment: 240.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2007-05-31
Primary completion date: 2017-05-31
Completion date: 2020-05-31
Clinical trial NCT02770378: A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
Official title: A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
Sponsor: University of Ulm (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-11-30
Primary completion date: 2018-10-31
Completion date: 2020-12-31
Plan to share individual participant data: NO
Clinical trial NCT06301308: A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial
Official title: A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial
Sponsor: Second Xiangya Hospital of Central South University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: The standard measures of anaesthesia in cystoscopy are not uniform internationally, and given this, we were unable to recruit the first participant in the study.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2023-10-01
Primary completion date: 2024-02-29
Completion date: 2024-02-29
Plan to share individual participant data: NO
Clinical trial NCT03187405: Intraventricular Fibrinolysis for Aneurysmal Subarachnoid Hemorrhage.
Official title: Intraventricular Fibrinolysis Versus External Ventricular Drainage Alone in Aneurysmal Subarachnoid Hemorrhage: a Randomized Controlled Trial.
Acronym: FIVHeMA
Sponsor: University Hospital, Caen (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: SUSPENDED 
Why stopped: Slow recruitment rate
Enrollment: 440.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2018-02-21
Primary completion date: 2024-03-15
Completion date: 2024-03-15
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03682055: Phase 1/2a Study of VK-2019 in Patients With Epstein-Barr Virus (EBV)-Positive Nasopharyngeal Carcinoma (NPC)
Official title: Phase 1/2a Open Label, Multicenter Clinical Trial of a Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus Positive Nasopharyngeal Cancer, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Sponsor: Cullinan Therapeutics Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Lack of efficacy
Enrollment: 14.0 (ACTUAL)
Number of arms: 4.0
Start date: 2019-04-04
Primary completion date: 2020-06-23
Completion date: 2020-08-08
Plan to share individual participant data: NO
Clinical trial NCT04341116: Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Official title: A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Sponsor: I-Mab Biopharma US Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 149.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-04-11
Primary completion date: 2022-02-07
Completion date: 2022-02-07
Plan to share individual participant data: NO
Clinical trial NCT04176393: A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation
Official title: A Phase 1, Multicenter, Single-Arm Study Evaluating Pharmacokinetic, Pharmacodynamic, Safety, and Clinical Efficacy of Orally Administered Ivosidenib in Chinese Subjects With Relapsed or Refractory Acute Myeloid Leukemia With an IDH1 Mutation
Sponsor: CStone Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 30.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-11-12
Primary completion date: 2021-02-18
Completion date: 2023-01-18
Clinical trial NCT05716295: A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
Official title: A Phase 1/2, Open-Label, Multicenter Study of MDK-703 as a Monotherapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced or Metastatic Solid Tumors (ORCHID-1)
Acronym: ORCHID-1
Sponsor: Medikine, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: Corporate decision
Enrollment: 26.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-02-08
Primary completion date: 2024-04-30
Completion date: 2024-04-30
Plan to share individual participant data: NO
Clinical trial NCT03660683: Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus
Official title: Cardio-Protective of Effect of Saxagliptin and Dapagliflozin Combination on Endothelial Progenitor Cells in Patients With Type 2 Diabetes
Sponsor: George Washington University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Sponsor did not want to continue funding the study
Enrollment: 15.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-10-22
Primary completion date: 2021-03-11
Completion date: 2021-12-10
Limitations and caveats: Study is limited by the small cohort used in each group. Many visit 2 data points missing, reported analysis only performed with visit 1 and 3 data.
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03106987: A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.
Official title: A Phase IIIb, Randomised, Double-blind, Placebo-controlled, Multicentre Study of Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer Previously Treated With a PARPi and Responding to Repeat Platinum Chemotherapy
Acronym: OReO
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 220.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-06-08
Primary completion date: 2021-02-15
Completion date: 2022-02-17
Baseline population: Full analysis set (FAS) consisted of all randomised patients analysed on an intent-to-treat (ITT) basis.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT03191162: Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease.
Official title: Phase II Clinical Trial for the Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease in Adult Patients. Berenice Project
Acronym: MULTIBENZ
Sponsor: Hospital Universitari Vall d'Hebron Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 238.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-04-21
Primary completion date: 2020-09-21
Completion date: 2021-03-16
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04624672: Treatment of GLP-1 for Diabetic Bariatric Patients
Official title: GLP-1 Agonists as Neoadjuvant Therapy for Surgical Treatment of Type 2 Diabetes: A Randomized Controlled Trial
Acronym: NOVO-GLP1
Sponsor: Geisinger Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Poor enrollment
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-08-25
Primary completion date: 2022-07-18
Completion date: 2022-08-17
Baseline population: Due to low recruitment numbers (\>5), no data analysis was completed because total number of patients recruited is too low to ensure patient confidentiality.
Plan to share individual participant data: NO
Clinical trial NCT03961555: Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies
Official title: A Phase 2b Randomized Blinded Study to Evaluate SYN023 Compared to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies in Adults With Different Rabies Exposure Risks
Acronym: ARPEP
Sponsor: Synermore Biologics Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 448.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-03
Primary completion date: 2021-12-23
Completion date: 2021-12-23
Plan to share individual participant data: NO
Clinical trial NCT04677543: Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium Complex
Official title: A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, Multicenter Study to Validate Patient-Reported Outcome Instruments in Adult Subjects With Newly Diagnosed Nontuberculous Mycobacterial (NTM) Lung Infection Caused by Mycobacterium Avium Complex (MAC)
Acronym: ARISE
Sponsor: Insmed Incorporated (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 99.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-12-22
Primary completion date: 2023-05-09
Completion date: 2023-05-09
Baseline population: Intent-to-treat (ITT) Analysis Set comprises all participants who were randomized.
Plan to share individual participant data: NO
Clinical trial NCT04171700: A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
Official title: A Phase 2 Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes
Acronym: LODESTAR
Sponsor: pharmaand GmbH (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study was terminated due to a change in development priorities.
Enrollment: 83.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-01-16
Primary completion date: 2022-06-08
Completion date: 2022-07-15
Plan to share individual participant data: YES
IPD sharing description: De-identified datasets for study results will be made available to qualified researchers in compliance with applicable privacy laws and data protection regulations.~Data will be provided by Clovis Oncology.
IPD time frame: Data will be made available to qualified researchers after the primary, secondary, and/or exploratory outcomes of the study are reported or published and for 1 year thereafter.
IPD access criteria: Requests for de-identified datasets will be made available to qualified researchers following submission of a methodologically sound proposal to medinfo@clovisoncology.com.
Clinical trial NCT00766779: HCT Versus CT in Elderly AML
Official title: Randomized Phase III Study Comparing Conventional Chemotherapy to Low Dose Total Body Irradiation-Based Conditioning and HCT From Related and Unrelated Donors as Consolidation Therapy for Older Patients With AML in 1st Complete Remission
Sponsor: European Society for Blood and Marrow Transplantation (NETWORK)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Recommendation of DMC
Enrollment: 126.0 (ACTUAL)
Number of arms: 2.0
Start date: 2010-01-31
Primary completion date: 2020-12-31
Completion date: 2020-12-31
Clinical trial NCT03311750: Anti-EGFR Therapy Rechallenge in Combination With Chemotherapy in Patients With Advanced Colorectal Cancer
Official title: Single-arm Phase II Study of Panitumumab Rechallenge in Combination With Oxaliplatin or Irinotecan-based Chemotherapy in Patients With RAS Wild Type Advanced Colorectal Cancer.
Acronym: A-REPEAT
Sponsor: Hellenic Cooperative Oncology Group (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: It was considered that the recruitment of the remaining 10 patients required of the trial will not be possible soon.
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-03-26
Primary completion date: 2021-03-31
Completion date: 2021-05-20
Clinical trial NCT03953677: Evaluation of the Effect of Dexmedetomidine on Phenylephrine Response During Refractory Septic Shock
Official title: A Randomized Controlled Pilot Study Evaluating the Effect of Dexmedetomidine on Phenylephrine Response During Refractory Septic Shock
Acronym: Adress-Pilot
Sponsor: Centre Hospitalier Universitaire Dijon (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Excess mortality in one arm of the study that led to discontinuation of enrollment
Enrollment: 32.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-27
Primary completion date: 2023-01-31
Completion date: 2023-03-22
Clinical trial NCT04639804: Pharmacokinetic Interaction Between Tegoprazan and NSAIDs After Multiple Oral Dosing in Healthy Male Volunteers
Official title: An Open-label, Randomized, Crossover Study to Evaluate the Pharmacokinetic Interaction Between Tegoprazan and Non-steroidal Anti-inflammatory Drugs (NSAIDs) After Multiple Oral Dosing in Healthy Male Volunteers
Sponsor: HK inno.N Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 3.0
Start date: 2020-06-06
Primary completion date: 2020-07-26
Completion date: 2020-07-29
Clinical trial NCT03056833: Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
Official title: Phase I Trial of Ribociclib (Ribociclib (LEE-011)) With Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
Sponsor: University of Pittsburgh (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 35.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-06-10
Primary completion date: 2020-06-01
Completion date: 2022-08-01
Plan to share individual participant data: NO